Hazel Crest, Illinois Clinical Trials

A listing of Hazel Crest, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
Phase III Study Assessing the Efficacy Safety and Immunogenicity of SOK583A1 Versus Eylea in Patients With Neovascular Age-related Macular Degeneration

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants …

Sandoz Investigational Site
 (4.0 away) Contact site
  • 0 views
  • 17 Jul, 2021
  • +37 other locations
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

rifampin
hydrochlorothiazide
measurable disease
neutrophil count
fluorouracil
Ingalls Memorial Hospital
 (3.0 away) Contact site
  • 65 views
  • 22 Jul, 2021
  • +978 other locations
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study

A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.

Community Hospital
 (9.6 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +6 other locations
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery …

lobular carcinoma
lobular carcinoma in situ
tumor cells
invasive breast cancer
diabetes
Loyola Center for Cancer Care and Research
 (8.7 away) Contact site
  • 335 views
  • 21 Jul, 2021
  • +903 other locations
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs. A side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that can be used to treat triple-negative …

HER2
advanced breast cancer
cancer
erbb2
breast cancer
Ingalls Cancer Care / Ingalls Memorial Hospital
 (3.0 away) Contact site
  • 179 views
  • 20 Jul, 2021
  • +59 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II IIIA and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses …

pemetrexed
gemcitabine
pembrolizumab
lung carcinoma
mk-3475
Ingalls Memorial Hospital ( Site 0044)
 (3.0 away) Contact site
  • 551 views
  • 21 Jul, 2021
  • +237 other locations
A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

primary cancer
growth factor
treatment regimen
bone marrow procedure
EGFR
Ingalls Memorial Hosp /ID# 165876
 (3.0 away) Contact site
  • 49 views
  • 10 Jul, 2021
  • +51 other locations
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

hodgkin's disease
mantle cell lymphoma
ibrutinib
diffuse large b-cell lymphoma
lymphoma
TG Therapeutics Investigational Trial Site
 (3.0 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +201 other locations
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

overweight or obesity
body mass index
cardiovascular disease
Novo Nordisk Investigational Site
 (18.7 away) Contact site
  • 7712 views
  • 18 Jul, 2021
  • +1164 other locations
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

epidermal growth factor receptor
epidermal growth factor
tyrosine
systemic therapy
c-MET
Ingalls Memorial Hosp /ID# 203228
 (3.0 away) Contact site
  • 118 views
  • 20 Jul, 2021
  • +346 other locations